These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8227758)

  • 1. The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders.
    Simhandl C; Denk E; Thau K
    J Affect Disord; 1993 Aug; 28(4):221-31. PubMed ID: 8227758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up.
    Post RM; Leverich GS; Rosoff AS; Altshuler LL
    J Clin Psychopharmacol; 1990 Oct; 10(5):318-27. PubMed ID: 2124216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inter-episodic morbidity and drop-out under carbamazepine and lithium in the maintenance treatment of bipolar disorder.
    Kleindienst N; Greil W
    Psychol Med; 2002 Apr; 32(3):493-501. PubMed ID: 11989994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The lithium concentration of the blood plasma in combined therapy with lithium carbonate and carbamazepine].
    Skorik AI
    Farmakol Toksikol; 1991; 54(4):57-9. PubMed ID: 1786831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes.
    Weisler RH; Kalali AH; Ketter TA;
    J Clin Psychiatry; 2004 Apr; 65(4):478-84. PubMed ID: 15119909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are serum lithium levels related to the polarity of recurrence in bipolar disorders? Evidence from a multicenter trial.
    Kleindienst N; Severus WE; Greil W
    Int Clin Psychopharmacol; 2007 May; 22(3):125-31. PubMed ID: 17414737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The recruitment process for a multicenter study on the long-term prophylactic treatment of affective disorders.
    Greil W; Ludwig-Mayerhofer W; Steller B; Czernik A; Giedke H; Müller-Oerlinghausen B; Osterheider M; Rudolf GA; Sauer H; Tegeler J
    J Affect Disord; 1993 Aug; 28(4):257-65. PubMed ID: 8227762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbamazepine in the prophylaxis of mood disorders.
    Stuppaeck C; Barnas C; Miller C; Schwitzer J; Fleischhacker WW
    J Clin Psychopharmacol; 1990 Feb; 10(1):39-42. PubMed ID: 2307735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of carbamazepine and lithium on affective disorders.
    Okuma T
    Neuropsychobiology; 1993; 27(3):138-45. PubMed ID: 8232828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lithium prophylaxis of manic-depressive disorder: daily lithium dosing schedule versus every second day.
    Jensen HV; Plenge P; Mellerup ET; Davidsen K; Toftegaard L; Aggernaes H; Bjørum N
    Acta Psychiatr Scand; 1995 Jul; 92(1):69-74. PubMed ID: 7572251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Misdiagnosis of bipolar affective disorder as personality disorder.
    Tyrer SP; Brittlebank AD
    Can J Psychiatry; 1993 Nov; 38(9):587-9. PubMed ID: 8080501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.
    Denicoff KD; Smith-Jackson EE; Disney ER; Ali SO; Leverich GS; Post RM
    J Clin Psychiatry; 1997 Nov; 58(11):470-8. PubMed ID: 9413412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late non-response to lithium prophylaxis in bipolar patients: prevalence and predictors.
    Maj M; Pirozzi R; Magliano L
    J Affect Disord; 1996 Jun; 39(1):39-42. PubMed ID: 8835652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.
    Juruena MF; Ottoni GL; Machado-Vieira R; Carneiro RM; Weingarthner N; Marquardt AR; Fleig SS; Broilo L; Busnello EA
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb; 33(1):94-9. PubMed ID: 19007842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum and red cell folate and affective morbidity in lithium prophylaxis.
    McKeon P; Shelley R; O'Regan S; O'Broin J
    Acta Psychiatr Scand; 1991 Mar; 83(3):199-201. PubMed ID: 2031463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study.
    Peselow ED; Clevenger S; IsHak WW
    Int Clin Psychopharmacol; 2016 Jul; 31(4):218-23. PubMed ID: 26523730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hypothalamic-pituitary-thyroid axis in patients maintained on lithium prophylaxis for years: high triiodothyronine serum concentrations are correlated to the prophylactic efficacy.
    Baumgartner A; von Stuckrad M; Müller-Oerlinghausen B; Gräf KJ; Kürten I
    J Affect Disord; 1995 Jun; 34(3):211-8. PubMed ID: 7560549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The first lithium clinic in Hong Kong: a Chinese profile.
    Lee S
    Aust N Z J Psychiatry; 1992 Sep; 26(3):450-3. PubMed ID: 1417631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depot antipsychotics in bipolar affective disorder.
    White E; Cheung P; Silverstone T
    Int Clin Psychopharmacol; 1993; 8(2):119-22. PubMed ID: 8102150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lithium- and carbamazepine-associated sinus node dysfunction: nine-year experience in a psychiatric hospital.
    Steckler TL
    J Clin Psychopharmacol; 1994 Oct; 14(5):336-9. PubMed ID: 7806689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.